Finance

Lists
BBIO:NASDAQ
BridgeBio Pharma Inc
USD 66,14
-1,65%
(-1,11) 1D
USD 66,49
+0,53% (+0,35)
Pre-market
Closed: 5 Okt., 16:00:02 GMT-4  ·   USD
All symbols
SymbolPriceChange% Change
Generating top insights for BBIO...
Open
USD 67,40
High
USD 68,08
Low
USD 65,46
Mkt. cap
12,93 mjd
Avg. vol.
2,52 m
Volume
85,00
52-wk high
USD 93,42
52-wk low
USD 52,75
EPS
-USD 3,57
Beta
0,97
Shares outstanding
195,49 m
No. of employees
1 k
Open
USD 67,40
High
USD 68,08
Low
USD 65,46
Mkt. cap
12,93 mjd
Avg. vol.
2,52 m
Volume
85,00
52-wk high
USD 93,42
52-wk low
USD 52,75
EPS
-USD 3,57
Beta
0,97
Shares outstanding
195,49 m
No. of employees
1 k
News stories
From web sources and news partners
About BridgeBio Pharma Inc
CEONeil Kumar
Employees1 k
Founded2015
HeadquartersPalo Alto, Kalifornië, Verenigde State van Amerika
Sector-
Websitebridgebio.com
Analyst ratings
Based on 17 analysts giving stock ratings to BBIO in the past 3 months
Strong buy
Buy
16
Hold
1
Sell
0
12-month forecast
Based on 17 Wall Street analysts offering 12 month price targets for BBIO in the last 3 months.
Highest
Current USD 66,14
USD 157,00 (+137,38%)
Average
USD 111,44 (+68,49%)
Lowest
USD 94,00 (+42,12%)
Analyst
Recommendation
Action
Price target
Projected
Date
Ram Selvaraju
H.C. Wainwright
Buy
Reiterated
USD 120,00
+81,4%
10/06/2026
Eliana Merle
Barclays
Buy
Maintained
USD 157,00
+137,4%
09/30/2026
Tyler Van Buren
TD Cowen
Buy
Reiterated
USD 110,00
+66,3%
09/24/2026
Cory Kasimov
Evercore ISI
Buy
Maintained
USD 130,00
+96,6%
09/14/2026
Salim Syed
Mizuho Securities
Buy
Maintained
USD 110,00
+66,3%
08/31/2026
Andrew Tsai
Jefferies
Buy
Maintained
USD 110,00
+66,3%
08/31/2026
Biren Amin
Piper Sandler
Buy
Maintained
USD 115,00
+73,9%
08/31/2026
Joshua Schimmer
Cantor Fitzgerald
Buy
Maintained
USD 110,00
+66,3%
08/29/2026
Luca Issi
RBC Capital
Buy
Maintained
USD 100,00
+51,2%
08/14/2026
Whitney Ijem
Canaccord Genuity
Buy
Maintained
USD 106,00
+60,3%
08/12/2026
Eric Joseph
Citi
Hold
Maintained
USD 94,00
+42,1%
08/12/2026
Anupam Rama
J.P. Morgan
Buy
Reiterated
USD 111,00
+67,8%
08/12/2026
Danielle Brill
Truist Financial
Buy
Maintained
USD 107,00
+61,8%
08/12/2026
Myles Minter
William Blair
Buy
Reiterated
-
-
08/11/2026
Sean Laaman
Morgan Stanley
Buy
Reiterated
USD 97,00
+46,7%
08/11/2026
Derek Archila
Wells Fargo
Buy
Reiterated
USD 102,00
+54,2%
08/11/2026
Jason Zemansky
Bank of America Securities
Buy
Reiterated
USD 104,00
+57,2%
08/11/2026
Unknown Analyst
Wells Fargo
Buy
Reiterated
USD 102,00
+54,2%
08/11/2026
Tiago Fauth
Raymond James
Buy
Maintained
USD 98,00
+48,2%
06/17/2026
Martin Auster
Raymond James
Hold
Downgraded
-
-
05/26/2026
Unknown Analyst
Citi
Hold
Initiated
-
-
05/19/2026
William Pickering
Bernstein
Buy
Reiterated
USD 114,00
+72,4%
05/08/2026
Paul Choi
Goldman Sachs
Buy
Maintained
USD 116,00
+75,4%
05/08/2026
Matt Phipps
William Blair
Buy
Reiterated
-
-
05/02/2026
Lisa Walter
RBC Capital
Buy
Initiated
USD 100,00
+51,2%
04/08/2026
Trevor Allred
Oppenheimer
Buy
Maintained
USD 81,00
+22,5%
02/25/2026
Last report
10 Aug. 2026
Fiscal period
Q2 2026
EPS / Est. (USD)
-USD 0,78 / -USD 0,58
-33,87%miss
Revenue / Est. (USD)
243,68 m / 219,71 m
+10,91%beat
Fiscal Q2 2026 earnings call
Waiting for the earnings call
At a glance
Insights from the latest news and reports
Previous reportsAll values in USD
Loading Previous Earnings...
Revenue
Net income
All values in USD
Sep. 2025
Des. 2025
Mrt. 2026
Jun. 2026
Revenue
120,70 m
154,18 m
194,52 m
243,68 m
Cost of goods sold
6,56 m
8,11 m
9,94 m
15,05 m
Cost of revenue
6,56 m
8,11 m
9,94 m
15,05 m
Research and development expenses
112,87 m
116,42 m
126,64 m
149,45 m
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
137,62 m
158,08 m
163,90 m
186,26 m
Operating expense
250,50 m
274,50 m
290,53 m
335,71 m
Total operating expenses
257,06 m
282,61 m
300,47 m
350,76 m
Operating income
-136,36 m
-128,43 m
-105,96 m
-107,08 m
Other non operating income
16,46 m
11,82 m
4,25 m
5,59 m
EBT including unusual items
-186,48 m
-194,76 m
-166,56 m
-155,89 m
EBT excluding unusual items
-177,64 m
-183,62 m
-166,56 m
-155,89 m
Income tax expense
-1,54 m
-120,00 k
-
-
Effective tax rate
0,83%
0,06%
-
-
Other operating expenses
-
-
-
-
Net income
-182,74 m
-192,86 m
-164,04 m
-152,22 m
Net profit margin
-151,40%
-125,09%
-84,33%
-62,47%
Earnings per share
-0,72
-0,94
-0,84
-0,78
Interest and investment income
6,24 m
4,33 m
6,25 m
6,66 m
Interest expense
-48,15 m
-50,31 m
-52,82 m
-54,62 m
Net interest expenses
-41,91 m
-45,98 m
-46,57 m
-47,96 m
Depreciation and amortization charges
-
-
-
-
EBITDA
-134,96 m
-127,00 m
-104,77 m
-106,03 m
Gain or loss from assets sale
-
-
-
-
Insider transactions
Insider transactions data is drawn from third-party sources. Learn more
Insider
Position
Type
Date
Shares
Amount
Page 1
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer
Google-programme